基于siRNA的治疗候选药物,针对PRDM2抑制肺癌进展
Sanjay Kumar1, Md Zubbair Malik2, Maya Chaturvedi3
1School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India; Nanofluidiks Pvt. Ltd., Jawaharlal Nehru University-Foundation for Innovation, New Delhi 110067, India.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|November 22, 2025
概括
这项研究介绍了ARIZ-047,一种新的siRNA疗法,针对肺癌中的瘤原蛋白RIZ2蛋白. 通过抑制RIZ2和调节Wnt通路,ARIZ-047有效降低了肺癌细胞活力和瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因治疗 基因治疗
背景情况:
- 肺癌是全球癌症相关死亡的主要原因之一.
- 编码RIZ1和RIZ2的PRDM2基因在肺癌中经常失调,RIZ2的过度表达促进了瘤的进展.
- 向瘤性RIZ2是一个潜在的治疗策略.
研究的目的:
- 评估ARIZ-047的疗效,一种向致癌RIZ2异型的siRNA,作为潜在的肺癌治疗方法.
- 研究RIZ2抑制对肺癌细胞活力,基因表达和瘤生长的影响.
- 探索Wnt信号通路在RIZ2介导的肺癌进展中的作用.
主要方法:
- 利用ARIZ-047,一种小干扰RNA (siRNA),在肺癌细胞中选择性抑制RIZ2表达.
- 进行了转录组分析,以评估ARIZ-047治疗后的基因表达变化.
- 在肺癌异种移植小鼠模型中,评估了囊在向纳米颗粒 (T-CaP) 中的ARIZ-047的体内疗效.
主要成果:
- 在A549肺癌细胞系中,ARIZ-047治疗导致RIZ1表达增加和活力下降.
- 转录组分析揭示了Wnt信号通路的调节和增殖和转移相关基因的下调.
- 在体内研究表明,在用T-CaP封装ARIZ-047.7治疗的异种移植模型中,显著减少瘤大小和减少RIZ2表达.
结论:
- 通过选择性抑制瘤性RIZ2.2,ARIZ-047显示出作为肺癌向治疗的潜力.
- 这项研究表明,Wnt信号通路与RIZ2过度表达和肺癌进展有关.
- 使用纳米颗粒的ARIZ-047的向输送增强了其在体内治疗功效.
相关概念视频
siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Experimental RNAi
7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K


